Shots:
- Alteogen has entered into an option & license agreement with Novartis for the development & commercialization of SC products leveraging ALT-B4 powered by Alteogen’s Hybrozyme tech
- As per the deal, Novartis can obtain exclusive rights to develop & commercialize SC formulations of multiple products using Alteogen’s ALT-B4, with Alteogen eligible for ~$3.223B in option fees & milestones as well as royalties if all options & milestones are achieved
- ALT-B4 is a human recombinant hyaluronidase enzyme developed using Alteogen’s Hybrozyme tech. It temporarily depolymerizes hyaluronan in the extracellular matrix to facilitate the large-volume SC delivery of drugs, that are normally administered as IV
Ref: PRnewswire | Image: Alteogen & Novartis | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
